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The life span of patients with primary and secondary immunodeficiency is increasing 
due to recent improvements in therapeutic strategies. While the incidence of primary 
immunodeficiencies (PIDs) is 1:10,000 births, that of secondary immunodeficiencies 
are more common and are associated with posttransplantation immune dysfunction, 
with immunosuppressive medication for human immunodeficiency virus or with human 
T-cell lymphotropic virus infection. After infection, malignancy is the most prevalent 
cause of death in both children and adults with (PIDs). PIDs more often associated with 
cancer include common variable immunodeficiency (CVID), Wiskott–Aldrich syndrome, 
ataxia-telangiectasia, and severe combined immunodeficiency. This suggests that a 
protective immune response against both infectious non-self-(pathogens) and malignant 
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self-challenges (cancer) exists. The increased incidence of cancer has been attributed 
to defective elimination of altered or “transformed” cells and/or defective immunity 
towards cancer cells. The concept of aberrant immune surveillance occurring in PIDs is 
supported by evidence in mice and from patients undergoing immunosuppression after 
transplantation. Here, we discuss the importance of PID defects in the development 
of malignancies and the current limitations associated with molecular pathogenesis of 
these diseases and emphasize the need for further knowledge of how specific mutations 
can modulate the immune system to alter immunosurveillance and thereby play a key 
role in the etiology of malignancies in PID patients.
Keywords: primary immunodeficiency, malignancy
iNTRODUCTiON
The earliest evidence that individuals with primary immuno-
deficiencies (PIDs) develop cancer was reported in 1963 (1, 2). 
An increasing number of reports subsequently indicated that 
subjects with primary abnormalities of the immune system 
are at a high risk for developing cancer (3–6) and PID biology 
represents a rapidly developing area of clinical immunology. PIDs 
are inherited disorders of the immune system in which at least 
one, and often more, immune component is decreased, missing, 
or has an inappropriate function. PIDs comprise more than 130 
different heterogeneous disorders that affect various aspects of 
immune development and function as well as the morphology 
of the immune system (7–10). PIDs are rare with a prevalence in 
the United States of 1:1200 live births (11), and the overall risk 
for children with PIDs of developing malignancy is estimated 
at 4–25% (12, 13). The type of malignancy that is seen is highly 
dependent on the precise PID, the age of the patient, and probably 
viral infection indicating that different pathogenic mechanisms 
may be implicated in each case (12).
As stated above, PIDs were originally described as rare, to only 
occur in infants and young children, and to be associated with 
severe clinical symptoms. However, advances in gene sequencing 
technologies, such as whole exome sequencing, have revealed that 
they are much more common than originally appreciated and are 
present in older children, adolescents, and adults, and can present 
with relatively mild clinical disease in some patients (14, 15).
PIDs are classified according to which component of the 
immune system is primarily involved. Defects in adaptive 
immune responses include antibody deficiency syndromes, 
combined immunodeficiencies (CIDs), and severe combined 
immunodeficiency (SCID) (16), whereas defects in innate immu-
nity comprise disorders of phagocytes, and toll-like receptor 
(TLR)-mediated signaling and complement (17). All these forms 
of disease are characterized by increased susceptibility to recur-
rent infections and/or severe infections with the susceptibility 
to specific pathogens dependent upon the nature of the specific 
immune defect (18).
Immune dysregulation is present in some forms of PIDs, while 
other forms of PID are more complex and immunodeficiency 
represents only a part of the phenotype (immunodeficiency 
syndromes) (19, 20). The early detection of patients with PID is 
critically important as effective therapy is available for virtually 
all of the different disorders but is most beneficial when instituted 
before target organ damage has occurred (e.g., in the lung) by 
infection or by autoimmunity (21). Similarly, early recognition 
of primary immunodeficiency may lead to a precise genetic diag-
nosis, which in turn may be important to the family in planning 
their future reproductive options (22).
Genomic instability due to defective DNA repair processes 
and other unknown mechanisms in PID patients leads to an 
enhanced risk of cancer. We have reviewed here the etiology, 
pathogenesis, clinical, and laboratory features of each of the 
various categories of PIDs and highlighted their association with 
various malignancies.
THe LiNK BeTweeN PiDs AND 
MALiGNANCieS
Primary immunodeficiencies are occasionally referred to as 
inborn errors of immunity, inherited immunodeficiencies, herit-
able immune defects, or congenital immunodeficiencies. In all 
cases, it is explicit or implicit that the primary lesions are present 
in the germline, whether due to a de novo mutation or due to a 
mutation inherited from a parent carrying the mutation. It has 
also become evident that a normal cellular and clinical pheno-
type may be restored in some patients with PIDs when somatic 
mutations occur in the hematopoietic cell lineage (23, 24). As 
predicted by Burnet, there is an increased predisposition to 
malignancy in patients with severe primary immunodeficiency 
(1, 13, 25, 26).
PIDs are a heterogeneous group of rare disorders character-
ized by impaired humoral and/or cell-mediated immunity, in 
the absence of any recognized cause such as drug treatment or 
human immunodeficiency virus (HIV). The most common PID 
syndromes are common variable immunodeficiency (CVID) 
with a 25-year mortality rate of 24% mostly due to lymphoma 
(18%), chronic pulmonary disease (11%), and X-linked agam-
maglobulinemia (XLA), which accounts for between 80 and 90% 
of all cases (21, 27, 28). This compares with the survival rate of 
92% (males) and 94% (females) within the general population 
(27). There is an enhanced incidence of several cancers including 
lymphoma and of stomach, breast, bladder, and cervical epithelial 
cancers in these patients with CVID associated with the presence 
of defective humoral immunity (12, 13, 25, 26). This highlights 
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the importance of an effective immune response against infection 
in the prevention of oncogenesis.
Common variable immune Deficiency
Common variable immune deficiency (CVID) is characterized 
by recurrent sino-pulmonary infections, autoimmune disorders, 
and granulomatous disease with an increased risk of malignancy 
(12- to 18-fold greater than in the general population) (29–34). 
CVID affects both children and adults, with an estimated 
prevalence of 1:25–50,000 (35, 36). The hallmark of CVID is 
hypogammaglobulinemia due to impaired B cell differentiation. 
CVID is heterogeneous, with most patients suffering mainly from 
infections, while others are particularly prone to non-infectious 
complications. These differences correlate with the particular 
B cell phenotype present in each patient (37).
An increased risk of malignancy particularly that of lym-
phoma and gastric cancer is associated with CVID (38–41). 
Indeed, malignancy is recognized as one of the five clinical 
CVID phenotypes proposed by Chapel and colleagues (38). 
In this classification, patients with polyclonal lymphadenopa-
thy were shown to have fivefold increased risk of lymphoid 
malignancy (38). Lymphoid malignancy generally occurs late in 
disease and in patients with pre-existing polyclonal lymphocytic 
infiltration (38). However, lymphoma can appear in young 
pediatric CVID patients in the absence of previous polyclonal 
lymphadenopathy (42).
Lymphoma is one of the more severe complications of CVID, 
but the driver(s) of this increased risk are unclear, although it 
seems to be multifactorial with the interplay of genetics, immune 
dysregulation, and chronic infectious agents including non-
oncogenic and oncogenic viruses such as Epstein–Barr virus 
(EBV) being important (43). This increase in infection, therefore, 
may be a critical driver of malignancy in patients with CVID. 
CVID-associated lymphomas are more likely to be of B cell origin 
with a predominance of non-Hodgkin lymphoma (NHL), and 
these usually occur in the fourth to seventh decades of life and 
are rarely seen in children. NHL is frequently extranodal and usu-
ally EBV-negative (43), and although the parotid gland, sinuses, 
orbital cavity, and stomach can be affected, the majority of cases 
affects the lung (44, 45).
HYPeR-ige SYNDROMe  
(JOB’S SYNDROMe)
Job’s syndrome is a complex CID disease that was first described 
in 1966 and named in reference to the Biblical character Job who 
was “smote with sore boils” (46). The description of the syndrome 
was refined after the realisation that in addition to the occur-
rence of recurrent boils, eczema, and pneumonias, these patients 
also had very high serum IgE levels (47). Two distinct entities 
have been recognized: the classical hyper-IgE syndrome, which 
is inherited in an autosomal-dominant pattern [autosomal-
dominant hyper-IgE syndrome (AD-HIES)], and the autosomal 
recessive hyper-IgE syndrome. The vascular, skeletal, and con-
nective tissue problems seen in AD-HIES reflect the multisystem 
status of the disorder (48, 49).
A mutation in the signal transducer and the activator of the 
transcription 3 (STAT3) gene has been identified in the major-
ity of AD-HIES patients, which results in impaired Th17 cell 
differentiation and downregulation of antimicrobial responses 
(50–55). Chronic mucocutaneous candidiasis (CMC) patients 
with a dominant-negative STAT3 mutation present with a 
decreased number of central memory CD4+ and CD8+ lym-
phocytes and an increased number of naive T cells (56). Due to 
this loss of memory T cells, patients with HIES are predisposed 
to develop varicella zoster virus reactivation and prolonged EBV 
viremia. The impaired IL-17 + T cell differentiation and function 
is a plausible explanation for the susceptibility of HIES patients 
to CMC (51, 57). However, such patients are also susceptible to 
infections by pyogenic bacteria, especially Staphylococcus aureus 
causing recurrent skin and lung infections due to a failure of Th17 
CD4+ cells to recruit neutrophils to the site of infection and to 
upregulate antimicrobial peptides (58).
Reduced levels of IL-17 are linked to mucocutaneous infec-
tions with Candida albicans in man (59–63) and to enhanced 
susceptibility to Candida and Klebsiella infections in mice (64, 
65). Th17 cells are also important for IL-22 secretion, which is 
critical for beta-defensin production and subsequent protection 
against S. aureus infection in individuals with eczema (66). This 
suggests that the S. aureus-infected abscesses seen in AD-HIES 
are due to reduced beta-defensin production secondary to the 
lack of Th17 cells. Beta defensins are also expressed in the lung 
and might in part explain the susceptibility to pneumonias (67).
The reason why AD-HIES subjects have a very high serum 
IgE levels is unknown, although this has been linked to impaired 
IL-21 signaling (68). However, human B cells differ from those 
in mice in that IL-21 acts synergistically with IL-4 to increase 
IgE production in man (69), whereas IgE levels in serum are 
increased in IL-21R- and IL-21-deficient mice (68, 70). Therefore, 
the lack of IL-21 might be associated with less, not more, IgE 
in man. The combined effect of IL-4 and IL-21 on IgE secretion 
was also unrelated to alterations in expression of their receptors 
because neither IL-4 nor IL-21 enhanced the level of CD40L-
induced IL-21R or IL-4R expression on B cells. It is possible that 
the increased IgE reflects a lack of suppression of IL-21 and/or 
IL-4 by IL-10 or IFNγ. It is noteworthy that this cardinal feature 
of AD-HIES has not yet been clearly explained.
A similar, but distinct, syndrome was reported in 2004, which 
was characterized by extremely elevated serum IgE levels, severe 
eczema, and recurrent bacterial and viral skin infections as well as 
by sino-pulmonary infections (71). In comparison to AD-HIES, 
these individuals lack the somatic features such as the charac-
teristic faces, scoliosis, and the failure of baby teeth to exfoliate. 
In addition, although pneumonias occur in autosomal recessive 
hyper IgE syndrome (AR-HIES), pneumatoceles do not form.
Autosomal recessive hyper IgE syndrome has a much higher 
rate of coetaneous viral infections such as molluscum conta-
giosum, herpes simplex, and varicella infections. They also 
have frequent neurologic disease, ranging from facial paralysis 
to hemiplegia often due to CNS vasculitis. Mortality is high in 
younger patients with AR-HIES with sepsis being more frequent 
than in AD-HIES. Two other autosomal recessive forms of HIES 
are caused by mutations in the gene for tyrosine kinase 2 (Tyk2). 
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Kilic et  al. (72) described a patient with Tyk2 deficiency who 
displayed none of the other three cardinal features of HIES: atopic 
dermatitis and eczema, staphylococcal infections of the skin and 
lung, or high serum IgE concentrations; his highest recorded IgE 
concentration being 218 IU/mL at the age of 16 years. A diagnosis 
of Tyk2 deficiency should be contemplated in patients with BCG 
clinical disease, particularly in the presence of unusually severe 
herpes virus infection, even in the absence of cardinal features 
of HIES. This diagnosis may also apply to patients with other 
mycobacterial diseases, whether they are tuberculous or atypical, 
as well as those with infections caused by other intramacrophage 
pathogens, such as Salmonella and Brucella.
A related syndrome is seen in patients with defects in the gene 
dedicator of cytokinesis (DOCK) 8 (73–78). Patients with DOCK8 
mutations have elevated IgE levels and the presence of allergy, 
eczema, cutaneous viruses, and malignancies (79). Contrary to 
its initial description as a form of hyper-IgE syndrome, DOCK8 
deficiency can be regarded as a CID disease that features eczema 
and elevated IgE much like the Wiskott–Aldrich syndrome 
(WAS) (80). On the other hand, phosphoglucomutase 3 (PGM3) 
deficiency is not associated with cold abscesses, CMC, retained 
childhood dentition, and joint hypermobility that are seen very 
commonly in patients with STAT3 mutations. PGM3 deficiency 
can present with elevated IgE, atopic dermatitis, bronchiectasis, 
and scoliosis, which help to distinguish this disorder from the two 
best-known diseases with elevated IgE: STAT3 and DOCK8 defi-
ciencies. Although PGM3-deficient patients occasionally have 
viral skin infections, they were not as prevalent as in DOCK8 
deficiency. Primary neurocognitive deficits are seen in PGM3 
deficiency but not in either STAT3 or DOCK8 deficiencies (81).
In the context of this review, HIES patients have a much higher 
risk of developing aggressive B cell lymphomas, which may be 
linked to abnormalities in STAT3/IL-21-dependent differentia-
tion of B cells into plasma cells with the possible involvement of 
T follicular helper cells (82–84). B-cells are also important in the 
formation, progression, and metastases of many other cancers 
including lung cancer and melanoma (85, 86). Viral infection 
in AD-HIES and AR-HIES is associated with an increased risk 
of cancer over and above that seen with PIDs alone, suggesting 
that the inability of these patients to mount an efficient immune 
response to infection may allow pre-malignant cells to grow 
unchecked and develop into cancer. The role of Th17 and memory 
T-cells in this process needs to be better defined.
CHRONiC MUCOCUTANeOUS 
CANDiDiASiS AND CMC DiSeASe
Several PIDs typically characterized by CMC and impaired IL-17-
mediated immunity have recently been identified (87). CMC in 
such patients may be part of a complex clinical phenotype exem-
plified by a dominant-negative STAT3 deficiency, interleukin 
(IL)-12Rβ1 and IL-12p40 deficiencies, and autoimmune polyen-
docrine syndrome type 1 (APS-1) (57, 88–90). In a subgroup of 
PIDs, a predisposition to superficial candidiasis may be the only, 
or at least the dominant, characteristic of the underlying genetic 
disorder [chronic mucocutaneous candidiasis disease (CMCD)] 
(91). Inborn errors of IL-17-mediated immunity lead to CMC 
in humans, and an autosomal-dominant mutation in IL-17F and 
autosomal recessive mutations in IL-17RA or IL17-RC predispose 
patients to complete CMC. In contrast, the heterozygous STAT1 
mutations associated with CMC are gain-of-function (92–94).
Candida albicans is the most common species isolated from 
patients with CMC. Candidal infections develop and persist, 
usually beginning during infancy but sometimes during early 
adulthood. The fungus may cause mouth infections (thrush) and 
infections of the scalp, skin, and nails. Membranes lining the 
mouth, eyelids, digestive tract, and vagina may also be infected. 
In infants, the first symptoms are often difficult to treat thrush 
and diaper rash. The disorder may cause one or more nails to 
thicken, crack, and become discolored. A disfiguring rash may 
cover the face and scalp. The rash is crusted and thick and may 
ooze and when present on the scalp may cause hair to fall out (95).
Th17 cytokines are important for the prevention of infec-
tion with Candida colonizing the mucocutaneous surfaces (57, 
61, 96). The differentiation, expansion, and maintenance of 
human IL-17-producing T cells is regulated by a set of cytokines 
including IL-1β, IL-6, IL-21, IL-23, and TGF-β along with the 
transcription factors STAT3, retinoic acid-related orphan recep-
tor (ROR)-γt, and interferon regulatory factor 4 (IRF4) (48, 91, 
97–100). However, alternative mechanisms to explain the unique 
vulnerability to infection of the skin, mucous membranes, and 
the lung in HIES patients may be required.
Chronic mucocutaneous candidiasis is associated with squa-
mous cell cancers of the esophagus and of the oral cavity (95). 
This provides a link between the site of repeated or recurrent 
infection and a defect in the Th17 response. These cancers are 
also seen in patients with autosomal recessive autoimmune poly-
endocrinopathy syndrome type I (AR APS-I), which is caused by 
mutations in the protein autoimmune regulator (AIRE), who are 
not susceptible to any other infectious disease (91). The distinct 
mechanisms that underpin the increased incidence of esophagal 
cancer in CMC patients require further study (101).
FAMiLiAL HeMOPHAGOCYTiC 
LYMPHOHiSTiOCYTOSiS
The rare autosomal recessive disorder termed familial 
hemophagocytic lymphohistiocytosis (FHL) is due to defects in 
natural killer (NK) and cytotoxic T lymphocytes (CTLs), result-
ing in a multisystem inflammatory disease with persistent fever 
and hepatosplenomegaly associated with cytopenias and blood 
metabolic alterations. Type 2 FHL (FHL2) is linked to mutations 
in the PRF1 gene encoding human perforin, which represent 
13–58% of the cases reported to date depending on the ethnicity 
of the patient (102–108). To date, more than 70 mutations in 
PRF1 have been described in FHL2. Although most of these are 
missense mutations, it is unclear how they affect protein expres-
sion and function (109–111). Studies of missense mutations from 
patient-derived cells and cell lines are limited by the infrequent 
occurrence of individuals with homozygous mutations.
Overall, there is a striking similarity between the biologic 
changes induced by proinflammatory cytokines and the clinical 
and laboratory findings in FHL (112). The proinflammatory 
cytokines soluble IL-2 receptor, IL-6, interferon-γ, and TNF-α 
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are reported to be commonly elevated in FHL (112–114). More 
recent studies indicated elevated plasma levels of IL-12 and IL-10 
in these patients. The former stimulates the production of Th1 
cytokines, and the latter suppresses Th1 responses. In contrast, 
the levels of the Th2-stimulating cytokine IL-4 were not increased 
(115). It is reasonable to assume, therefore, that most of the symp-
toms, signs, and the laboratory alterations in FHL patients are 
mediated by proinflammatory cytokines.
Mutations in the PRF1 gene result in a reduced ability of 
immune cells to perform their essential immunosurveillance 
roles, particularly against spontaneous lymphomas, which 
accounts for the enhanced risk of lymphoma in FHL patients. 
Furthermore, a third of the patients with interleukin-10 receptor 
(IL-10R) deficiency, which results in abnormal Th1 responses and 
a loss of immunosurveillance capacity, develop B-cell lympho-
mas in the first decade of their life. The lymphomas uniformly 
contained amplifications of c-rel, activation of inflammatory 
nuclear factor κB (NF-κB)-induced target genes, and defective 
intratumoral CD81 T-cell tumor immunosurveillance (116).
igA DeFiCieNCY
Selective IgA deficiency is one of the most prevalent PID subtypes 
with an estimated prevalence of ~1:600 (117). Although selective 
IgA deficiency is asymptomatic in many patients, clinical manifes-
tations include respiratory and GI infections, atopy, autoimmune 
diseases, and lymphoid and GI malignancies, which occur later 
in life (118). Since IgA deficiency and CVID share a common 
genetic basis, they may be considered as a spectrum ranging 
from the mild reductions in IgA levels to severe deficiencies of 
multiple antibodies in CVID (119). The progression from mild or 
asymptomatic selective IgA deficiency to CVID is possible and, if 
noted, should prompt initiation of Ig replacement therapy to pre-
vent infectious and pulmonary complications (120). Patients with 
selective IgA deficiency have a high incidence of gastrointestinal 
cancers, highlighting the immunoprotective role of IgA against 
this type of malignancy.
Patients with X-linked immunodeficiency with hyper-IgM, 
caused by mutations in the CD40 ligand, have a high incidence 
of tumors of the pancreas and liver (121). Interestingly, a primary 
cutaneous marginal zone lymphoma (PCMZL) with the sequen-
tial development of nodal marginal zone lymphoma has been 
recently reported in a patient with selective immunoglobulin A 
deficiency (122). This is in addition to a previous report of a γ/δ 
type abdominal T-cell non-Hodgkin’s lymphoma in a patient with 
selective IgA deficiency (123).
DNA RePAiR DiSORDeRS
A number of rare PIDs are the result of genetic defects in DNA 
repair that also lead to immune deficits and susceptibility to 
malignancy (124, 125).
ATAXiA-TeLANGieCTASiA
Ataxia-telangiectasia (AT) is an autosomal recessive disorder and 
is characterized by progressive cerebellar ataxia presenting in 
infancy, oculocutaneous telangiectasia, and dysarthria (126, 127). 
Cells from patients with AT have a reduced ability to activate cell 
cycle checkpoints, which is seen particularly following radiation 
exposure for example (γ-irradiation or radiomimetic agents) 
because of mutations in the AT mutated (ATM) gene. The ATM 
gene normally acts as a sensor of double-stranded DNA breakage 
(124), and the predisposition to leukemia is thought to be related 
to excessive production of DNA translocations (126).
Not surprisingly, therefore, AT has the highest risk for 
malignancy of any PID (126, 128), and the overall incidence of 
cancer among patients with AT is as high as 40%. Leukemias and 
lymphomas are particularly prevalent, appearing in AT patients 
with rates 70- to 500-fold and 200- to 750-fold, respectively, 
higher than in the general population (127). Interestingly, there 
is an increased risk of breast cancer among heterozygote AT car-
riers, who are otherwise generally healthy with the greatest risk in 
elderly AT patients who are smokers (129). The ability of immune 
checkpoint blockers to treat a number of different cancers also 
indicates a key role for defects in immune function being critical 
for the development of cancer.
NiJMeGeN BReAKAGe SYNDROMe
Nijmegen breakage syndrome (NBS) is a rare autosomal recessive 
disorder closely related to AT that, although it occurs worldwide, 
it has a greater prevalence in people of Central and Eastern 
European descent (130). The defective NBS gene (NBS1, nibrin, 
or p95) is a component within the same pathway as ATM and 
both proteins are part of a multi-subunit complex involved in 
correcting radiation-induced chromosomal aberrations (124, 
131). Immune deficiency is generally severe and characterized 
by both humoral, such as agammaglobulinemia, IgA deficiency, 
and IgG2 and IgG4 deficiency, and cellular immunity, including 
lymphopenia, decreased CD31+ and CD41+ T helper cells, and a 
decreased CD41:CD81 T suppressor cell ratio (132). The physical 
features of NBS are typified by microcephaly, short stature, and 
“bird-like” faces (131, 132).
Not surprisingly, therefore, NBS exhibits many similarities to 
AT, including humoral and T-cell defects, radiosensitivity, and 
chromosomal instability, which are linked to immune dysfunc-
tion and to a high risk of malignancy.
wiSKOTT–ALDRiCH SYNDROMe
Wiskott–Aldrich syndrome is a rare X-linked primary immu-
nodeficiency characterized by microthrombocytopenia, eczema, 
recurrent infections, and an increased incidence of autoimmunity 
and malignancies. The disease is caused by mutations in the WAS 
gene, which is expressed only in hematopoietic cells (133). The 
overall incidence of cancer in WAS patients is unclear, although 
18% of WAS subjects in a small study were reported as having 
malignant lymphoma (134). In all but one patient, the diagnosis 
of lymphoma was made ante-mortem and located predominantly 
in extranodal sites or within the brain. There was no involvement 
of peripheral lymph nodes (134). A higher incidence of NHL has 
also been described in WAS patients (135).
6Mortaz et al. Malignancy in PID Patients
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 365
PHAGOCYTe DiSORDeRS
Severe congenital neutropenia (SCN) is a heterogeneous disorder 
due to the arrest of myelopoiesis maturation at the promyelocyte/
myelocyte stage, resulting in neutropenia with systemic neutro-
phil blood counts <0.5 × 109/L. Patients with SCN present with 
recurrent, severe infections during infancy and persistent neutro-
penia. A total of 50–60% of cases are associated with mutations 
in the elastase (ELA) 2 gene, and >50 unique mutations have 
been identified. Other common genetic defects associated with 
SCN include biallelic mutations in the hematopoietic cell-specific 
Lyn substrate 1 (HCLS1)-associated protein X-1 (HAX1) or in 
glucose-6-phosphatase, catalytic, 3 (G6PC3) genes. For most 
patients, daily treatment with granulocyte colony-stimulating 
factor (G-CSF) results in elevated blood neutrophil counts and 
reduces the risk of infection (136).
Heterozygous mutations in GATA2 resulting in GATA2 
deficiency is a recently described disorder of hematopoiesis, 
lymphatics, and immunity. GATA2 is a zinc finger transcription 
factor essential for differentiation of immature hematopoietic 
cells (137). In addition, GATA2 regulates phagocytosis by alveo-
lar macrophages (138), and GATA2 overexpression in alveolar 
macrophages increases phagocytic activity up to threefold (139).
Patients with GATA2 mutations present with numerous 
diagnoses and symptoms including MDS, AML, chronic 
myelomonocytic leukemia (CMML), severe viral, disseminated 
mycobacterial and invasive fungal infections, pulmonary arte-
rial hypertension, warts, panniculitis, human papillomavirus 
(HPV)-positive tumors, EBV-positive tumors, venous throm-
bosis, lymphedema, sensorineural hearing loss, miscarriage, and 
hypothyroidism (140).
A very high rate of leukemia is seen in subjects with SCN. 
This is predominantly AML, but subjects may also suffer ALL, 
CML, and bi-phenotypic leukemia (141). Point mutations in 
the colony-stimulating factor 3 receptor (granulocyte) (GCSFR 
or CSF3R) gene are seen in bone marrow cells from most SCN 
patients who develop leukemia, suggesting that such mutations 
are highly predictive, although not essential, for malignant 
transformation in these subjects (142). CSF3R mutations are very 
specific for patients with SCN and are not found in patients with 
primary AML or other forms of chronic neutropenia requiring 
long-term treatment with G-CSF (142). These data emphasize 
the critical role of immune neutrophils in immunosurveillance 
of pre-cancerous cells.
DeFeCTS iN THe iMMUNe ReSPONSe iN 
PiD PATieNTS DRiveS MALiGNANCY
The data presented above suggest that a defective immune 
response in PID patients is associated with a greater incidence 
of cancer independent of whether the defect is primary or sec-
ondary. For example, lower serum Ig levels are associated with 
malignancies, highlighting the importance immunodeficiency 
in the predisposition to neoplasia (143). This risk is amplified by 
the enhanced susceptibility to viral infections in patients with 
PIDs (144). Defective immunosurveillance is undoubtedly a 
major factor in the risk of developing cancer, and this is seen 
most evidently in cells with a strong antigenic potential that 
have undergone viral induction. Supporting this concept is the 
fact that lymphoma, an immune system-related malignancy, is 
the most common cancer subtype in immunodeficient patients 
(12, 145). NHL and Hodgkin’s disease (HD) account for 48.6 
and 10%, respectively, of the malignancies seen in patients with 
PIDs according to the Immunodeficiency Cancer Registry (ICR) 
database (124, 146). The overall risk for cancer developing in 
children with PID is estimated to range from 4 to 25% (12, 
147). Finally, EBV infection in WAS patients induces lymphoma 
(135, 148), and the occurrence of lymphoproliferative disorders 
(LPDs) in patients with PID has been documented for nearly 
40 years.
Mutations in the X-linked inhibitor of apoptosis (XIAP) are 
associated with a rare primary immunodeficiency. XIAP is an 
anti-apoptotic molecule but is also important in many other 
pathways, including control of innate immunity and in the 
negative regulation of inflammation (149). Loss of XIAP results in 
reduced NOD ligand-induced proinflammatory cytokine expres-
sion in both mouse and man (150–152). Furthermore, the ability 
of the pattern recognition receptor dectin-1 to recognize fungal 
β-glucan from fungi is modulated by XIAP (153). Under these 
conditions, XIAP regulated β-glucan-induced NF-κB and MAPK 
activation, cytokine production, and phagocytosis via ubiquitina-
tion of BCL10. The T-cell receptor (TCR) pathway activation of 
NF-κB also requires BCL10 and XIAP (151).
X-linked inhibitor of apoptosis deficiency is mostly reported 
in young boys who can be affected during the first few months of 
life, with symptoms being most severe in the youngest patients. 
The most frequent clinical manifestations are HLH (54%), recur-
rent splenomegaly (57%), and IBD (26%). Viral infection is often 
the trigger for HLH, with EBV (60% of cases) with cytomegalo-
virus (CMV) and human herpes virus 6 (HHV-6) being the most 
important, although symptoms may occur without an identified 
infectious agent (149).
These PIDs are a heterogeneous group of genetically deter-
mined disorders, which give rise to a number of diverse and vari-
able LPDs. The susceptibility of developing LPD is associated with 
the type of PID presence, but accurate quantification of this risk 
is difficult since PIDs are rare. Analysis of case reports provides 
risk estimates of 0.7–15% (154). The extent to which primary 
immunodeficiency in man leads to increased cancer development 
is therefore unclear and generally relies on gene-targeted murine 
studies (155). For example, recombination-activating gene 2 
(RAG2)-deficient mice that lack both T and B cells are more 
susceptible to spontaneous and carcinogen-induced carcinomas 
(156), while mice lacking γδT cells are highly susceptible to 
cutaneous carcinogenesis (157).
In contrast, interferon-α/β (IFN-α/β) and IFN-γ protect mice 
against both spontaneous and carcinogen-induced cancers (156, 
158–160). Moreover, perforin, which is used by cytotoxic lym-
phocytes to kill target cells and is defective in FHL, is important 
for the surveillance of spontaneous lymphoma in mice (161).
Collectively, the human and mouse data reveal a consist-
ent association between primary immunodeficiency and an 
increased incidence of cancers. Overall, two major mechanisms 
FiGURe 1 | Schematic cartoon indicating the various defects in humoral and cellular compartments, which drive the development of malignancies. 
For more information, please refer to the text.
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appear to be important for this link, prevention of infection and 
immunosurveillance and elimination of pre-malignant cells, and 
these are described in more detail below.
iNSUFFiCieNT FUNCTiONiNG OF THe 
iMMUNe SYSTeM ALLOwS iNFeCTiON 
AND PReveNTS eFFeCTive 
iMMUNOSURveiLLANCe
The immune system confers protection against viral and bacterial 
pathogens and parasitic worms. Although evidence exists for the 
immune system targeting invading cancers, there are less data 
demonstrating the immunological eradication of pre-cancerous 
lesions in man and thereby preventing cancer (143, 162). For 
example, although organ transplant recipients who are treated 
with immunosuppressive drugs are more prone to cancer devel-
opment (163, 164), the majority of posttransplantation lympho-
mas was associated with EBV infection (165). Thus, most of the 
lymphomas reported in PID patients are likely to be secondary 
events resulting from reduced antiviral immunity, rather than a 
direct effect of reduced antitumor immunity.
The HIV1 virus causes acquired immunodeficiency by selec-
tively infecting and killing CD4+ T cells, and this is associated 
with an elevated risk of cancer. These cancers are generally linked 
to oncogenic viruses such as Kaposi sarcoma [caused by human 
herpes virus 8 (HHV8)], Hodgkin’s lymphoma and NHL (EBV), 
anal and cervical cancer (human papilloma virus), and liver 
cancer (hepatitis B and C viruses). Kaposi sarcoma, NHL, and 
cervical cancer are particularly frequent and are considered as 
acquired immunodeficiency syndrome (AIDS)-defining cancers 
(166). Blockade of the immune check-point molecules CTLA-4, 
PD-1, or PDL1 is of value in these cancers by potentiating the 
patient’s own immune response (167).
Elimination of pre-malignant cells can occur, and the 
importance of immune system in defending against cancers is 
exemplified by lymphocytes bearing the receptor killer cell lectin-
like receptor subfamily K, member 1 (KLRK1), which are able to 
recognize and eliminate stressed pre-malignant cells (168). Self-
proteins, such as MICA and MICB, are ligands for KLRK1 as are 
six different ULBP proteins that are poorly expressed in normal 
resting cells but whose cell surface expression is upregulated after 
treatment with DNA-damaging agents such as ionizing radiation 
and UV light (169, 170). Many freshly isolated lung, breast, kid-
ney, ovary, prostate, colon, and liver carcinomas express MICA 
and MICB (171). The expression of these KLRK1 ligands is also 
induced by oncogenic growth factors acting through their recep-
tors such as the epidermal growth factor receptor (EGFR) (172). 
The EGFR pathway is frequently dysregulated in human cancer, 
and EGFR activation may regulate the immunological visibility 
of stressed pre-malignant cells (169). KLRK1 knockout mice 
develop prostate adenocarcinomas and B cell lymphomas (173), 
and polymorphisms in the KLRK1 gene are associated with the 
susceptibility of developing liver and cervix cancers (174, 175).
In summary, the data from both man and mice suggest that the 
expression of stress-induced endogenous molecules associated 
with cell transformation may be used by the immune system to 
recognize and eliminate pre-malignant cells.
ROLe OF iNFeCTiOUS AGeNTS iN 
DRiviNG MALiGNANCY
The data to date suggest that the increase in viral infection seen 
in PIDs patients further enhanced the susceptibility to cancer, 
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although the precise mechanisms for this remain unclear. The 
impact of infectious agents on cancer risk has been investigated 
in CVID patients. High HHV8 copy numbers are present in the 
malignant lymph node of CVID patients with granulomas (176). 
In addition, there is a 13-fold increase in CD8+ T cells specific for 
CMV-derived peptides in CVID patients compared with controls 
(177). Clinical observations indicate that an exaggerated T cell 
response to CMV may exacerbate enteropathy in CVID patients 
(147). Moreover, Helicobacter pylori infection and pernicious 
anemia are risk predictors for gastric cancer in CVID patients 
and in the general population (42).
Epstein–Barr virus is an important co-factor for the 
development of CVID and can affect the host, either primarily 
during an immunocompromised state or following reactiva-
tion during a disease flare (12, 178). The range of lymphoid 
tumors linked with EBV includes HD, angioimmunoblastic 
lymphadenopathy, lymphomatoid granulomatosis, some forms 
of HIV-associated lymphoma, and primary central nervous 
system lymphomas. It is paradoxical that a ubiquitous virus 
which causes a generally benign and self-limiting infective 
illness of childhood or early adult life may also be responsible 
for such aggressive tumors. Further studies are required to 
delineate the mechanism(s) of EBV and other viral infections 
on cancer susceptibility.
PROGNOSiS AND PeRSPeCTiveS
We have described here how dysfunctions in the immune system 
of patients with PIDs can predispose patients to malignancies. 
Early treatment of the immunodeficiencies in some of these 
patients, before end organ damage has occurred, may reduce the 
risk of cancer, but clearly a greater understanding of the pathways 
responsible for this increased risk is needed. This may lead to the 
development of novel therapeutic agents that prevent cancer. In 
addition to the critical role in protection from infectious non-self-
pathogens, the immune system is also important in modulating 
malignant self-challenges (cancer). Numerous immune cells are 
involved in cancer surveillance and prevention including those 
of the adaptive (T and B cells) and innate (NK and macrophages) 
immune systems, and all of these are defective to a greater or 
lesser extent in patients with PID. However, our knowledge of the 
precise mechanisms by which the immune system fights cancer, 
particularly in relation to infection by non-oncogenic viruses, 
remains rudimentary at best, although an inaccurate antitumor 
immune response may occur (179). There is no inherent difference 
in cancer treatment response in patients with PID compared to 
in non-immunodeficient patients (124). However, since patients 
with PIDs often have disseminated tumors that require systemic 
cytotoxic therapy which is poorly tolerated, there is an increased 
risk for infection and end-organ damage. New drugs are needed 
for these patients directed against the oncogenic pathways linked 
to each PID, but in the meantime, effective and early treatment of 
the immune defects present in each PID may reduce the associ-
ated risk of cancer.
The causative associations between immune factors and onco-
logic processes can be a pathological two-way street. For example, 
immunocompetent patients with cancer can develop immune 
suppression secondary to the cancer, from chemotherapy or 
from posttransplant immunosuppressive therapy (180). This is 
particularly evident for B-cell chronic lymphocytic leukemia and 
associated hypogammaglobulinemia. As in patients with PID, 
infection control is paramount. Immunoglobulin replacement 
therapy has been shown to reduce the frequency of bacterial infec-
tions in patients with chronic lymphocytic leukemia (181–184) 
and NHL (182), and this may impact upon the subsequent risk 
of malignancy.
In conclusion, the increased incidence of cancer in patients 
with some types of PID is due to the inherent dysregulation of 
the immune response present and/or exposure to an infectious 
organism (Figure 1). It is only through greater understanding of 
how the specific mutations in each patient relate to and modify 
oncogenic pathways that we will prevent the development of 
these malignancies.
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